Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the home care setting, reported financial results for the three and twelve months ended December 31, 2013.
Deerfield Management Company announced that it has entered into an agreement to provide Wellfount Corporation with $15.0 million in funding. With these amounts, Wellfount will possess sufficient working capital to continue to expand the portfolio of long term care facilities in which its innovative pharmacy solution is implemented. Wellfount currently provides medications to over 3,000 residents in eight states, using a safe, cost effective approach that combines technologically sophisticated remote dispensing units with high touch, on-site customer service.
It was a long time coming, but Delphinus Medical Technologies Inc. started this year off with a big step toward entering the revenue stage. The Plymouth Township-based company announced Jan. 7 that the U.S. Food & Drug Administration had cleared the company to sell its SoftVue device used to detect breast cancer.
The life sciences sector in Michigan is growing, but a more coordinated approach could make it even stronger going forward, panelists told a packed house Monday at the Business Leaders for Michigan second annual leadership summit in East Lansing.
Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today provided ETC-1002 development program updates and reported its financial results for the fourth quarter and full year ended Dec. 31, 2013.
ArborMetrix, a leading provider of real-time healthcare analytics, announced that Mark McClellan, M.D., Ph.D, M.P.A., a senior fellow and director of the Health Care Innovation and Value Initiative at the Brookings Institution, is joining its Board of Directors.